<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39408968</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Transpulmonary Plasma Endothelin-1 Arterial:Venous Ratio Differentiates Survivors from Non-Survivors in Critically Ill Patients with COVID-19-Induced Acute Respiratory Distress Syndrome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10640</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910640</ELocationID><Abstract><AbstractText>Endothelin-1 (ET-1) is a potent vasoconstrictor produced by endothelial cells and cleared from circulating blood mainly in the pulmonary vasculature. In a healthy pulmonary circulation, the rate of local production of ET-1 is less than its rate of clearance. In the present study, we aimed to investigate whether the abnormal pulmonary circulatory handling of ET-1 relates to poor clinical outcomes in patients with coronavirus disease 2019 (COVID-19)-induced acute respiratory distress syndrome (ARDS). To this end, central venous and systemic arterial ET-1 plasma levels were simultaneously measured on Days 1 and 3 following ICU admission in mechanically ventilated COVID-19 patients with ARDS (COVID-19 ARDS, N = 18). Central venous and systemic arterial ET-1 plasma levels were also measured in two distinct SARS-CoV-2-negative mechanically ventilated critically ill patient groups, matched for age, sex, and critical illness severity, with ARDS (non-COVID-19 ARDS, N = 14) or without ARDS (non-COVID-19 non-ARDS, N = 20). Upon ICU admission, COVID-19-induced ARDS patients had higher systemic arterial and central venous ET-1 levels compared to the non-COVID-19 ARDS and non-COVID-19 non-ARDS patients (<i>p</i> &lt; 0.05), yet a normal systemic arterial:central venous (A:V) ET-1 ratio [0.63 (0.49-1.02)], suggesting that pulmonary ET-1 clearance is intact in these patients. On the other hand, the non-COVID-19 ARDS patients demonstrated abnormal ET-1 handling [A:V ET-1 ratio 1.06 (0.93-1.20)], while the non-COVID-19 non-ARDS group showed normal ET-1 handling [0.79 (0.52-1.11)]. On Day 3, the A:V ratio in all three groups was &lt;1. When the COVID-19 ARDS patients were divided based on 28-day ICU mortality, while their systemic arterial and central venous levels did not differ, the A:V ET-1 ratio was statistically significantly higher upon ICU admission in the non-survivors [0.95 (0.78-1.34)] compared to the survivors [0.57 (0.48-0.92), <i>p</i> = 0.027]. Our results highlight the potential importance of ET-1 as both a biomarker and a therapeutic target in critically ill COVID-19 patients. The elevated A:V ET-1 ratio in non-survivors suggests that the early disruption of pulmonary ET-1 handling may be a key marker of poor prognosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vassiliou</LastName><ForeName>Alice G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-4984-0476</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roumpaki</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6276-8937</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keskinidou</LastName><ForeName>Chrysi</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-4047-3588</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Athanasiou</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-1477-6243</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsipilis</LastName><ForeName>Stamatios</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2631-3809</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahaj</LastName><ForeName>Edison</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-7306-713X</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vrettou</LastName><ForeName>Charikleia S</ForeName><Initials>CS</Initials><Identifier Source="ORCID">0000-0002-1067-8849</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannopoulou</LastName><ForeName>Vassiliki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halioti</LastName><ForeName>Asimenia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0003-5606-0221</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferentinos</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimopoulou</LastName><ForeName>Ioanna</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2219-7292</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotanidou</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2508-500X</Identifier><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langleben</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Pulmonary Vascular Disease, Division of Cardiology, Azrieli Heart Center and Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Orfanos</LastName><ForeName>Stylianos E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>First Department of Critical Care Medicine &amp; Pulmonary Services, School of Medicine, National &amp; Kapodistrian University of Athens, "Evangelismos" Hospital, 10676 Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019332">Endothelin-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019332" MajorTopicYN="Y">Endothelin-1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">clearance</Keyword><Keyword MajorTopicYN="N">endothelin-1</Keyword><Keyword MajorTopicYN="N">prognosis</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39408968</ArticleId><ArticleId IdType="pmc">PMC11476705</ArticleId><ArticleId IdType="doi">10.3390/ijms251910640</ArticleId><ArticleId IdType="pii">ijms251910640</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., Cereda D., Coluccello A., Foti G., Fumagalli R., et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574–1581. doi: 10.1001/jama.2020.5394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.5394</ArticleId><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.2648</ArticleId><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanghavi D.K., Titus A., Caulfield T.R., David Freeman W. Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19. Med. Hypotheses. 2021;150:110564. doi: 10.1016/j.mehy.2021.110564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2021.110564</ArticleId><ArticleId IdType="pmc">PMC7985609</ArticleId><ArticleId IdType="pubmed">33823371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S., Huang X., Liu R., Lan Y., Lei Y., Zeng F., Tang X., He H. Comparison of COVID-19 Induced Respiratory Failure and Typical ARDS: Similarities and Differences. Front. Med. 2022;9:829771. doi: 10.3389/fmed.2022.829771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.829771</ArticleId><ArticleId IdType="pmc">PMC9196311</ArticleId><ArticleId IdType="pubmed">35712114</ArticleId></ArticleIdList></Reference><Reference><Citation>Beloncle F.M. Is COVID-19 different from other causes of acute respiratory distress syndrome? J. Intensive Med. 2023;3:212–219. doi: 10.1016/j.jointm.2023.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jointm.2023.02.003</ArticleId><ArticleId IdType="pmc">PMC10085872</ArticleId><ArticleId IdType="pubmed">37362866</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou A.G., Zacharis A., Keskinidou C., Jahaj E., Pratikaki M., Gallos P., Dimopoulou I., Kotanidou A., Orfanos S.E. Soluble Angiotensin Converting Enzyme 2 (ACE2) Is Upregulated and Soluble Endothelial Nitric Oxide Synthase (eNOS) Is Downregulated in COVID-19-induced Acute Respiratory Distress Syndrome (ARDS) Pharmaceuticals. 2021;14:695. doi: 10.3390/ph14070695.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14070695</ArticleId><ArticleId IdType="pmc">PMC8308597</ArticleId><ArticleId IdType="pubmed">34358119</ArticleId></ArticleIdList></Reference><Reference><Citation>Baratella E., Bussani R., Zanconati F., Marrocchio C., Fabiola G., Braga L., Maiocchi S., Berlot G., Volpe M.C., Moro E., et al. Radiological-pathological signatures of patients with COVID-19-related pneumomediastinum: Is there a role for the Sonic hedgehog and Wnt5a pathways? ERJ Open Res. 2021;7:00346-2021. doi: 10.1183/23120541.00346-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00346-2021</ArticleId><ArticleId IdType="pmc">PMC8381265</ArticleId><ArticleId IdType="pubmed">34435038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragnoli B., Da Re B., Galantino A., Kette S., Salotti A., Malerba M. Interrelationship between COVID-19 and Coagulopathy: Pathophysiological and Clinical Evidence. Int. J. Mol. Sci. 2023;24:8945. doi: 10.3390/ijms24108945.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24108945</ArticleId><ArticleId IdType="pmc">PMC10219009</ArticleId><ArticleId IdType="pubmed">37240292</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J. Clin. Investig. 1997;100:2153–2157. doi: 10.1172/JCI119751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI119751</ArticleId><ArticleId IdType="pmc">PMC508409</ArticleId><ArticleId IdType="pubmed">9410891</ArticleId></ArticleIdList></Reference><Reference><Citation>Mather K.J., Lteif A., Steinberg H.O., Baron A.D. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004;53:2060–2066. doi: 10.2337/diabetes.53.8.2060.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.53.8.2060</ArticleId><ArticleId IdType="pubmed">15277386</ArticleId></ArticleIdList></Reference><Reference><Citation>Banecki K., Dora K.A. Endothelin-1 in Health and Disease. Int. J. Mol. Sci. 2023;24:11295. doi: 10.3390/ijms241411295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241411295</ArticleId><ArticleId IdType="pmc">PMC10379484</ArticleId><ArticleId IdType="pubmed">37511055</ArticleId></ArticleIdList></Reference><Reference><Citation>D’Orléans-Juste P., Labonté J., Bkaily G., Choufani S., Plante M., Honoré J.C. Function of the endothelin(B) receptor in cardiovascular physiology and pathophysiology. Pharmacol. Ther. 2002;95:221–238. doi: 10.1016/S0163-7258(02)00235-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0163-7258(02)00235-8</ArticleId><ArticleId IdType="pubmed">12243796</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis J., Stewart D.J., Cernacek P., Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 1996;94:1578–1584. doi: 10.1161/01.CIR.94.7.1578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.94.7.1578</ArticleId><ArticleId IdType="pubmed">8840847</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis J., Cernacek P., Tardif J.C., Stewart D.J., Gosselin G., Dyrda I., Bonan R., Crépeau J. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am. Heart J. 1998;135:614–620. doi: 10.1016/S0002-8703(98)70276-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-8703(98)70276-5</ArticleId><ArticleId IdType="pubmed">9539476</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart D.J., Levy R.D., Cernacek P., Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann. Intern. Med. 1991;114:464–469. doi: 10.7326/0003-4819-114-6-464.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-114-6-464</ArticleId><ArticleId IdType="pubmed">1994793</ArticleId></ArticleIdList></Reference><Reference><Citation>Langleben D., DeMarchie M., Laporta D., Spanier A.H., Schlesinger R.D., Stewart D.J. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1993;148:1646–1650. doi: 10.1164/ajrccm/148.6_Pt_1.1646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/148.6_Pt_1.1646</ArticleId><ArticleId IdType="pubmed">8256914</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitzberg E., Lundberg J.M., Rudehill A. Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ. Shock. 1991;33:222–227.</Citation><ArticleIdList><ArticleId IdType="pubmed">2065442</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart D.J., Kubac G., Costello K.B., Cernacek P. Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J. Am. Coll. Cardiol. 1991;18:38–43. doi: 10.1016/S0735-1097(10)80214-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0735-1097(10)80214-1</ArticleId><ArticleId IdType="pubmed">2050938</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamane K. Endothelin and Collagen Vascular Disease: A Review with Special Reference to Raynaud’s Phenomenon and Systemic Sclerosis. Intern. Med. 1994;33:579–582. doi: 10.2169/internalmedicine.33.579.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.33.579</ArticleId><ArticleId IdType="pubmed">7827371</ArticleId></ArticleIdList></Reference><Reference><Citation>Uguccioni M., Pulsatelli L., Grigolo B., Facchini A., Fasano L., Cinti C., Fabbri M., Gasbarrini G., Meliconi R. Endothelin-1 in idiopathic pulmonary fibrosis. J. Clin. Pathol. 1995;48:330–334. doi: 10.1136/jcp.48.4.330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.48.4.330</ArticleId><ArticleId IdType="pmc">PMC502551</ArticleId><ArticleId IdType="pubmed">7615852</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan K.A., McMurtry I.F., Rodman D.M. Role of endothelin-1 in lung disease. Respir. Res. 2001;2:90–101. doi: 10.1186/rr44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/rr44</ArticleId><ArticleId IdType="pmc">PMC59574</ArticleId><ArticleId IdType="pubmed">11686871</ArticleId></ArticleIdList></Reference><Reference><Citation>Provencher S., Jais X., Yaici A., Sitbon O., Humbert M., Simonneau G. Clinical Challenges in Pulmonary Hypertension. Chest. 2005;128:622S–628S. doi: 10.1378/chest.128.6_suppl.622S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.128.6_suppl.622S</ArticleId><ArticleId IdType="pubmed">16373880</ArticleId></ArticleIdList></Reference><Reference><Citation>Clozel M., Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann. Med. 2005;37:2–12. doi: 10.1080/07853890410018925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890410018925</ArticleId><ArticleId IdType="pubmed">15902842</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca C., Abraham D., Renzoni E.A. Endothelin in Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Biol. 2011;44:1–10. doi: 10.1165/rcmb.2009-0388TR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2009-0388TR</ArticleId><ArticleId IdType="pubmed">20448055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolettis T.M., Barton M., Langleben D., Matsumura Y. Endothelin in Coronary Artery Disease and Myocardial Infarction. Cardiol. Rev. 2013;21:249–256. doi: 10.1097/CRD.0b013e318283f65a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CRD.0b013e318283f65a</ArticleId><ArticleId IdType="pubmed">23422018</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowich M., Choudhary G. Endothelin-1 levels and cardiovascular events. Trends Cardiovasc. Med. 2020;30:1–8. doi: 10.1016/j.tcm.2019.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2019.01.007</ArticleId><ArticleId IdType="pubmed">30765295</ArticleId></ArticleIdList></Reference><Reference><Citation>Böhm F., Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc. Res. 2007;76:8–18. doi: 10.1016/j.cardiores.2007.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2007.06.004</ArticleId><ArticleId IdType="pubmed">17617392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrosino P., Bachetti T., D’anna S.E., Galloway B., Bianco A., D’agnano V., Papa A., Motta A., Perrotta F., Maniscalco M. Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. J. Cardiovasc. Dev. Dis. 2022;9:136. doi: 10.3390/jcdd9050136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd9050136</ArticleId><ArticleId IdType="pmc">PMC9146906</ArticleId><ArticleId IdType="pubmed">35621847</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S.W., Ilyas I., Weng J.P. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin. 2023;44:695–709. doi: 10.1038/s41401-022-00998-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-022-00998-0</ArticleId><ArticleId IdType="pmc">PMC9574180</ArticleId><ArticleId IdType="pubmed">36253560</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham G.R., Kuc R.E., Althage M., Greasley P.J., Ambery P., Maguire J.J., Wilkinson I.B., Hoole S.P., Cheriyan J., Davenport A.P. Endothelin-1 is increased in the plasma of patients hospitalised with COVID-19. J. Mol. Cell. Cardiol. 2022;167:92–96. doi: 10.1016/j.yjmcc.2022.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2022.03.007</ArticleId><ArticleId IdType="pmc">PMC8941861</ArticleId><ArticleId IdType="pubmed">35339512</ArticleId></ArticleIdList></Reference><Reference><Citation>Turgunova L., Mekhantseva I., Laryushina Y., Alina A., Bacheva I., Zhumadilova Z., Turmukhambetova A. The Association of Endothelin-1 with Early and Long-Term Mortality in COVID-19. J. Pers. Med. 2023;13:1558. doi: 10.3390/jpm13111558.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm13111558</ArticleId><ArticleId IdType="pmc">PMC10672100</ArticleId><ArticleId IdType="pubmed">38003873</ArticleId></ArticleIdList></Reference><Reference><Citation>Miedema J., Schreurs M., van der Sar-van der Brugge S., Paats M., Baart S., Bakker M., Hoek R., Dik W.A., Endeman H., Van Der Velden V., et al. Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course. Front. Immunol. 2021;12:684142. doi: 10.3389/fimmu.2021.684142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.684142</ArticleId><ArticleId IdType="pmc">PMC8155664</ArticleId><ArticleId IdType="pubmed">34054876</ArticleId></ArticleIdList></Reference><Reference><Citation>Willems L.H., Nagy M., Ten Cate H., Spronk H.M.H., Groh L.A., Leentjens J., Janssen N.A.F., Netea M.G., Thijssen D.H.J., Hannink G., et al. Sustained inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction at 3 months after COVID-19. Thromb. Res. 2022;209:106–114. doi: 10.1016/j.thromres.2021.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.11.027</ArticleId><ArticleId IdType="pmc">PMC8642246</ArticleId><ArticleId IdType="pubmed">34922160</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahbazi S., Vahdat Shariatpanahi Z., Shahbazi E. Bosentan for high-risk outpatients with COVID-19 infection: A randomized, double blind, placebo-controlled trial. EClinicalMedicine. 2023;62:102117. doi: 10.1016/j.eclinm.2023.102117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102117</ArticleId><ArticleId IdType="pmc">PMC10404861</ArticleId><ArticleId IdType="pubmed">37554128</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonson M.S. Endothelins: Multifunctional renal peptides. Physiol. Rev. 1993;73:375–411. doi: 10.1152/physrev.1993.73.2.375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.1993.73.2.375</ArticleId><ArticleId IdType="pubmed">8475194</ArticleId></ArticleIdList></Reference><Reference><Citation>Galié N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 2004;61:227–237. doi: 10.1016/j.cardiores.2003.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardiores.2003.11.026</ArticleId><ArticleId IdType="pubmed">14736539</ArticleId></ArticleIdList></Reference><Reference><Citation>Chester A.H., Yacoub M.H. The role of endothelin-1 in pulmonary arterial hypertension. Glob. Cardiol. Sci. Pr. 2014;2014:62–78. doi: 10.5339/gcsp.2014.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.5339/gcsp.2014.29</ArticleId><ArticleId IdType="pmc">PMC4220438</ArticleId><ArticleId IdType="pubmed">25405182</ArticleId></ArticleIdList></Reference><Reference><Citation>Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W.P., Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1993;328:1732–1739. doi: 10.1056/NEJM199306173282402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199306173282402</ArticleId><ArticleId IdType="pubmed">8497283</ArticleId></ArticleIdList></Reference><Reference><Citation>Langleben D., Barst R.J., Badesch D., Groves B.M., Tapson V.F., Murali S., Bourge R.C., Ettinger N., Shalit E., Clayton L.M., et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 1999;99:3266–3271. doi: 10.1161/01.CIR.99.25.3266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.99.25.3266</ArticleId><ArticleId IdType="pubmed">10385501</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel R.P., Langleben D., Dupuis J. The endothelin system in pulmonary hypertension. Can. J. Physiol. Pharmacol. 2003;81:542–554. doi: 10.1139/y03-008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/y03-008</ArticleId><ArticleId IdType="pubmed">12839266</ArticleId></ArticleIdList></Reference><Reference><Citation>Langleben D., Dupuis J., Langleben I., Hirsch A.M., Baron M., Senécal J.L., Giovinazzo M. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest. 2006;129:689–695. doi: 10.1378/chest.129.3.689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.129.3.689</ArticleId><ArticleId IdType="pubmed">16537869</ArticleId></ArticleIdList></Reference><Reference><Citation>Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin. Chest Med. 2007;28:117–125. doi: 10.1016/j.ccm.2006.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2006.11.002</ArticleId><ArticleId IdType="pubmed">17338931</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacoub P., Amoura Z., Langleben D. Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008. Rev. Med. Interne. 2008;29:283–289. doi: 10.1016/j.revmed.2007.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.revmed.2007.12.005</ArticleId><ArticleId IdType="pubmed">18243424</ArticleId></ArticleIdList></Reference><Reference><Citation>Star G.P., Giovinazzo M., Langleben D. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: A potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension. Microvasc. Res. 2010;80:349–354. doi: 10.1016/j.mvr.2010.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2010.05.010</ArticleId><ArticleId IdType="pubmed">20594999</ArticleId></ArticleIdList></Reference><Reference><Citation>Horn E.M., Chakinala M., Oudiz R., Joseloff E., Rosenzweig E.B. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm. Circ. 2020;10:2045894020922799. doi: 10.1177/2045894020922799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2045894020922799</ArticleId><ArticleId IdType="pmc">PMC7219006</ArticleId><ArticleId IdType="pubmed">32426113</ArticleId></ArticleIdList></Reference><Reference><Citation>Badagliacca R., Sciomer S., Petrosillo N. Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe? J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant. 2020;39:729–730. doi: 10.1016/j.healun.2020.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2020.04.007</ArticleId><ArticleId IdType="pmc">PMC7162760</ArticleId><ArticleId IdType="pubmed">32360293</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabeh O.A., Matter L.M., Khattab M.A., Esraa M. The possible implication of endothelin in the pathology of COVID-19-induced pulmonary hypertension. Pulm. Pharmacol. Ther. 2021;71:102082. doi: 10.1016/j.pupt.2021.102082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2021.102082</ArticleId><ArticleId IdType="pmc">PMC8483983</ArticleId><ArticleId IdType="pubmed">34601121</ArticleId></ArticleIdList></Reference><Reference><Citation>Shilin D.S., Shapovalov K.G. Changes in Some Vascular Biomarkers in Patients with Severe COVID-19 with Various Degrees of Pulmonary Hypertension. Bull. Exp. Biol. Med. 2022;173:433–436. doi: 10.1007/s10517-022-05581-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10517-022-05581-5</ArticleId><ArticleId IdType="pmc">PMC9441327</ArticleId><ArticleId IdType="pubmed">36058981</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Jiang X., Xu S. Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: Mechanism of action and therapeutic potential. Drug Discov. Today. 2023;28:103788. doi: 10.1016/j.drudis.2023.103788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2023.103788</ArticleId><ArticleId IdType="pubmed">37742911</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Yuan T., Wang R., Gong D., Wang S., Du G., Fang L. Insights into Endothelin Receptors in Pulmonary Hypertension. Int. J. Mol. Sci. 2023;24:10206. doi: 10.3390/ijms241210206.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241210206</ArticleId><ArticleId IdType="pmc">PMC10299084</ArticleId><ArticleId IdType="pubmed">37373355</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahar S., Kanda S., Chatha U., Odoma V.A., Pitliya A., AlEdani E.M., Bhangu J.K., Javed K., Manshahia P.K., Yu A.K. Current Status of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension: A Combined Study Results and Pharmacology-Based Review. Cureus. 2023;15:e42748. doi: 10.7759/cureus.42748.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.42748</ArticleId><ArticleId IdType="pmc">PMC10467640</ArticleId><ArticleId IdType="pubmed">37654961</ArticleId></ArticleIdList></Reference><Reference><Citation>Druml W., Steltzer H., Waldhäusl W., Lenz K., Hammerle A., Vierhapper H., Gasic S., Wagner O.F. Endothelin-1 in adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1993;148:1169–1173. doi: 10.1164/ajrccm/148.5.1169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/148.5.1169</ArticleId><ArticleId IdType="pubmed">8239149</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanai L., Haynes W.G., MacKenzie A., Grant I.S., Webb D.J. Endothelin production in sepsis and the adult respiratory distress syndrome. Intensive Care Med. 1996;22:52–56. doi: 10.1007/BF01728331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01728331</ArticleId><ArticleId IdType="pubmed">8857438</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitaka C., Hirata Y., Nagura T., Tsunoda Y., Amaha K. Circulating endothelin-1 concentrations in acute respiratory failure. Chest. 1993;104:476–480. doi: 10.1378/chest.104.2.476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.104.2.476</ArticleId><ArticleId IdType="pubmed">8339637</ArticleId></ArticleIdList></Reference><Reference><Citation>Albertine K.H., Wang Z.M., Michael J.R. Expression of endothelial nitric oxide synthase, inducible nitric oxide synthase, and endothelin-1 in lungs of subjects who died with ARDS. Chest. 1999;116:101S–102S. doi: 10.1378/chest.116.suppl_1.101S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.116.suppl_1.101S</ArticleId><ArticleId IdType="pubmed">10424623</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano Y., Tasaka S., Saito F., Yamada W., Shiraishi Y., Ogawa Y., Koh H., Hasegawa N., Fujishima S., Hashimoto S., et al. Endothelin-1 level in epithelial lining fluid of patients with acute respiratory distress syndrome. Respirology. 2007;12:740–743. doi: 10.1111/j.1440-1843.2007.01115.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1843.2007.01115.x</ArticleId><ArticleId IdType="pubmed">17875064</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavsar T.M., Cerreta J.M., Liu M., Reznik S.E., Cantor J.O. Phosphoramidon, an endothelin-converting enzyme inhibitor, attenuates lipopolysaccharide-induced acute lung injury. Exp. Lung Res. 2008;34:141–154. doi: 10.1080/01902140701884430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01902140701884430</ArticleId><ArticleId IdType="pubmed">18307123</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii Y., Magder S., Cernacek P., Goldberg P., Guo Y., Hussain S.N. Endothelin receptor blockade attenuates lipopolysaccharide-induced pulmonary nitric oxide production. Am. J. Respir. Crit. Care Med. 2000;161:982–989. doi: 10.1164/ajrccm.161.3.9904094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.161.3.9904094</ArticleId><ArticleId IdType="pubmed">10712352</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuklin V., Kirov M., Sovershaev M., Andreasen T., Ingebretsen O.C., Ytrehus K., Bjertnaes L. Tezosentan-induced attenuation of lung injury in endotoxemic sheep is associated with reduced activation of protein kinase C. Crit. Care. 2005;9:R211–R217. doi: 10.1186/cc3497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc3497</ArticleId><ArticleId IdType="pmc">PMC1175881</ArticleId><ArticleId IdType="pubmed">15987392</ArticleId></ArticleIdList></Reference><Reference><Citation>Manitsopoulos N., Nikitopoulou I., Maniatis N.A., Magkou C., Kotanidou A., Orfanos S.E. Highly Selective Endothelin-1 Receptor A Inhibition Prevents Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice. Respiration. 2018;95:122–136. doi: 10.1159/000481201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000481201</ArticleId><ArticleId IdType="pubmed">29131071</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumas J.P., Bardou M., Goirand F., Dumas M. Hypoxic pulmonary vasoconstriction. Gen. Pharmacol. 1999;33:289–297. doi: 10.1016/S0306-3623(99)00026-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-3623(99)00026-9</ArticleId><ArticleId IdType="pubmed">10523066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato K., Morio Y., Morris K.G., Rodman D.M., McMurtry I.F. Mechanism of hypoxic pulmonary vasoconstriction involves ET(A) receptor-mediated inhibition of K(ATP) channel. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000;278:L434–L442. doi: 10.1152/ajplung.2000.278.3.L434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.2000.278.3.L434</ArticleId><ArticleId IdType="pubmed">10710514</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman D.E., Ronner L., Pinotti R., Taylor M.D., Sinha P., Calfee C.S., Hirayama A.V., Mastroiani F., Turtle C.J., Harhay M.O., et al. Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir. Med. 2020;8:1233–1244. doi: 10.1016/S2213-2600(20)30404-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30404-5</ArticleId><ArticleId IdType="pmc">PMC7567529</ArticleId><ArticleId IdType="pubmed">33075298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P., Matthay M.A., Calfee C.S. Is a “Cytokine Storm” Relevant to COVID-19? JAMA Intern. Med. 2020;180:1152–1154. doi: 10.1001/jamainternmed.2020.3313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3313</ArticleId><ArticleId IdType="pubmed">32602883</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson J.G., Simpson L.J., Ferreira A.M., Rustagi A., Roque J., Asuni A., Ranganath T., Grant P.M., Subramanian A., Rosenberg-Hasson Y., et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight. 2020;5:e140289. doi: 10.1172/jci.insight.140289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140289</ArticleId><ArticleId IdType="pmc">PMC7526438</ArticleId><ArticleId IdType="pubmed">32706339</ArticleId></ArticleIdList></Reference><Reference><Citation>Kox M., Waalders N.J.B., Kooistra E.J., Gerretsen J., Pickkers P. Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions. JAMA. 2020;324:1565–1567. doi: 10.1001/jama.2020.17052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17052</ArticleId><ArticleId IdType="pmc">PMC7489366</ArticleId><ArticleId IdType="pubmed">32880615</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchings S.D., Watchorn J., Trovato F., Napoli S., Mujib S.F., Hopkins P., McPhail M. Microcirculatory, Endothelial, and Inflammatory Responses in Critically Ill Patients With COVID-19 Are Distinct from Those Seen in Septic Shock: A Case Control Study. Shock. 2021;55:752–758. doi: 10.1097/SHK.0000000000001672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001672</ArticleId><ArticleId IdType="pubmed">33021572</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou A.G., Dimopoulou I., Jahaj E., Keskinidou C., Mastora Z., Orfanos S.E., Kotanidou A. Selection of the Appropriate Control Group Is Essential in Evaluating the Cytokine Storm in COVID-19. In Vivo. 2021;35:1295–1298. doi: 10.21873/invivo.12381.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/invivo.12381</ArticleId><ArticleId IdType="pmc">PMC8045069</ArticleId><ArticleId IdType="pubmed">33622933</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee C.S., Delucchi K.L., Sinha P., Matthay M.A., Hackett J., Shankar-Hari M., McDowell C., Laffey J.G., O’Kane C.M., McAuley D.F. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: Secondary analysis of a randomised controlled trial. Lancet Respir. Med. 2018;6:691–698. doi: 10.1016/S2213-2600(18)30177-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(18)30177-2</ArticleId><ArticleId IdType="pmc">PMC6201750</ArticleId><ArticleId IdType="pubmed">30078618</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranieri V.M., Rubenfeld G.D., Thompson B.T., Ferguson N.D., Caldwell E., Fan E., Camporota L., Slutsky A.S. Acute respiratory distress syndrome: The Berlin Definition. JAMA. 2012;307:2526–2533. doi: 10.1001/jama.2012.5669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2012.5669</ArticleId><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>